Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
AGA1
MCID: ALP061
MIFTS: 49

Alopecia, Androgenetic, 1 (AGA1)

Categories: Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Alopecia, Androgenetic, 1

About this section

MalaCards integrated aliases for Alopecia, Androgenetic, 1:

Name: Alopecia, Androgenetic, 1 57 13 37 71
Androgenetic Alopecia 57 20 43 17 71
Androgenic Alopecia 20 43
Androgenetic Alopecia; Aga 57
Female Pattern Baldness 43
Female Pattern Alopecia 71
Male Pattern Alopecia 43
Male Pattern Baldness 43
Alopecia Androgenetic 54
Pattern Baldness 43
Aga1 57
Aga 57

Characteristics:

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
autosomal dominant in males
recessive in females


HPO:

31
alopecia, androgenetic, 1:
Inheritance sex-limited autosomal dominant


Classifications:

MalaCards categories:
Global: Rare diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM® 57 109200
OMIM Phenotypic Series 57 PS203655
MedGen 41 C4049090
SNOMED-CT via HPO 68 278040002 56317004
UMLS 71 C0162311 C0263477 C4049090
Sources

Summaries for Alopecia, Androgenetic, 1

About this section
MedlinePlus Genetics : 43 Androgenetic alopecia is a common form of hair loss in both men and women. In men, this condition is also known as male-pattern baldness. Hair is lost in a well-defined pattern, beginning above both temples. Over time, the hairline recedes to form a characteristic "M" shape. Hair also thins at the crown (near the top of the head), often progressing to partial or complete baldness.The pattern of hair loss in women differs from male-pattern baldness. In women, the hair becomes thinner all over the head, and the hairline does not recede. Androgenetic alopecia in women rarely leads to total baldness.Androgenetic alopecia in men has been associated with several other medical conditions including coronary heart disease and enlargement of the prostate. Additionally, prostate cancer, disorders of insulin resistance (such as diabetes and obesity), and high blood pressure (hypertension) have been related to androgenetic alopecia. In women, this form of hair loss is associated with an increased risk of polycystic ovary syndrome (PCOS). PCOS is characterized by a hormonal imbalance that can lead to irregular menstruation, acne, excess hair elsewhere on the body (hirsutism), and weight gain.

MalaCards based summary : Alopecia, Androgenetic, 1, also known as androgenetic alopecia, is related to alopecia and androgenic alopecia. An important gene associated with Alopecia, Androgenetic, 1 is AFA1 (Alopecia, Androgenetic), and among its related pathways/superpathways are Translation Non-genomic (rapid) action of Androgen Receptor and Metabolism of steroid hormones. The drugs Acetylcysteine and Cetirizine have been mentioned in the context of this disorder. Affiliated tissues include prostate, skin and ovary, and related phenotypes are alopecia and endocrine/exocrine gland

GARD : 20 Androgenetic alopecia is a common form of hair loss in both men and women. In men, hair is usually lost in a well-defined pattern, beginning above both temples and is usually referred to as male-pattern baldness. Over time, the hairline recedes to form a characteristic 'M' shape. Hair also thins near the top of the head, often progressing to partial or complete baldness. The pattern of hair loss in women differs from men (female pattern hair loss). In women, the hair becomes thinner all over the head, and the hairline does not recede. Androgenetic alopecia in women rarely leads to total baldness. A variety of genetic and environmental factors likely play a role in causing this condition. Mutations in the AR gene have also been associated with androgenetic alopecia.

OMIM® : 57 Androgenetic alopecia is characterized by a loss of hair from the scalp that follows a defined pattern (Hamilton, 1951). It occurs in women as well as in men. It is caused by a shortening of the anagen (growth) phase and miniaturization of the hair follicle, which results in the formation of progressively thinner, shorter hair (Bergfeld, 1995). In men, the condition is often referred to as male pattern baldness (MPB) and appears to be androgen-dependent (Hamilton, 1942). The condition is hereditary, and follows a pattern that may be consistent with an autosomal dominant trait (Osborn, 1916). Linkage evidence for an autosomal locus on 3q26 (AGA1) has been identified (Hillmer et al., 2008). See 300710 (AGA2) for a discussion of X linkage of androgenetic alopecia. A third locus has been found on chromosome 20p11 (AGA3; 612421). (109200) (Updated 05-Mar-2021)

Wikipedia : 74 Pattern hair loss is hair loss that primarily affects the top and front of the scalp. In male-pattern... more...

Sources

Related Diseases for Alopecia, Androgenetic, 1

About this section

Diseases in the Alopecia, Androgenetic, 1 family:

Alopecia, Androgenetic, 2 Alopecia, Androgenetic, 3

Diseases related to Alopecia, Androgenetic, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 382)
# Related Disease Score Top Affiliating Genes
1 alopecia 31.9 SRD5A2 SRD5A1 SHBG AR
2 androgenic alopecia 31.5 TGFB2 SRD5A2 SRD5A1 SHBG CYP19A1 AR
3 prostatic adenoma 30.8 SRD5A1 SHBG AR
4 prostatic hyperplasia, benign 30.8 SRD5A2 SRD5A1 AR
5 sexual disorder 30.7 SHBG AR
6 prostatic hypertrophy 30.4 SRD5A2 SRD5A1 CYP19A1 AR
7 hair disease 30.4 SRD5A2 SHBG AR
8 acne 30.4 SRD5A1 SHBG CYP21A2 AR
9 hyperandrogenism 30.0 SRD5A1 SHBG CYP21A2 CYP19A1 AR
10 lipoid congenital adrenal hyperplasia 30.0 SRD5A1 CYP21A2 CYP19A1
11 polycystic ovary syndrome 29.8 SRD5A1 SHBG CYP21A2 CYP19A1 AR
12 prostate disease 29.8 SRD5A2 SRD5A1 CYP19A1 AR
13 male infertility 29.5 SHBG CYP21A2 CYP19A1 AR
14 premature menopause 29.3 SHBG CYP21A2 CYP19A1 AR
15 gynecomastia 29.3 SRD5A2 SRD5A1 SHBG CYP21A2 CYP19A1 AR
16 prostate cancer 28.0 XIAP TGFB2 SRD5A2 SRD5A1 SHBG CYP19A1
17 aspartylglucosaminuria 11.7
18 lysosomal storage disease 11.3
19 marie unna congenital hypotrichosis 11.3
20 glucocorticoid resistance, generalized 11.2
21 hypotrichosis 1 11.1
22 hypotrichosis simplex 11.1
23 fabry disease 11.1
24 angiokeratoma 11.1
25 orotic aciduria 10.9
26 lysosomal disease 10.9
27 rapidly involuting congenital hemangioma 10.9
28 alopecia areata 10.7
29 impotence 10.6
30 telogen effluvium 10.6
31 type 2 diabetes mellitus 10.5
32 frontal fibrosing alopecia 10.5
33 lipid metabolism disorder 10.3
34 inflammatory bowel disease 10.3
35 covid-19 10.3
36 seborrheic dermatitis 10.3
37 skin carcinoma 10.3
38 arteries, anomalies of 10.3
39 coronary heart disease 1 10.3
40 lipoprotein quantitative trait locus 10.3
41 diffuse alopecia areata 10.3
42 urolithiasis 10.3
43 infant gynecomastia 10.3
44 contact dermatitis 10.3
45 skin disease 10.3
46 hypertrichosis 10.3
47 celiac disease 1 10.2
48 diarrhea 10.2
49 body mass index quantitative trait locus 1 10.2
50 central centrifugal cicatricial alopecia 10.2

Graphical network of the top 20 diseases related to Alopecia, Androgenetic, 1:



Diseases related to Alopecia, Androgenetic, 1
Sources

Symptoms & Phenotypes for Alopecia, Androgenetic, 1

About this section

Human phenotypes related to Alopecia, Androgenetic, 1:

31
# Description HPO Frequency HPO Source Accession
1 alopecia 31 HP:0001596

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Hair:
early baldness

Clinical features from OMIM®:

109200 (Updated 05-Mar-2021)

MGI Mouse Phenotypes related to Alopecia, Androgenetic, 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.17 AR CFLAR CYP19A1 SRD5A1 SRD5A2 TGFB2
Sources

Drugs & Therapeutics for Alopecia, Androgenetic, 1

About this section

Drugs for Alopecia, Androgenetic, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Cetirizine Approved Phase 4 83881-51-0 2678
3
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
4
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
5 N-monoacetylcystine Phase 4
6 Neurotransmitter Agents Phase 4
7 Histamine Antagonists Phase 4
8 Histamine H1 Antagonists Phase 4
9
Histamine Phosphate Phase 4 51-74-1 65513
10 Anti-Allergic Agents Phase 4
11 Histamine H1 Antagonists, Non-Sedating Phase 4
12
Dutasteride Approved, Investigational Phase 3 164656-23-9 152945 6918296
13
Ethanol Approved Phase 2, Phase 3 64-17-5 702
14 Anti-Infective Agents Phase 2, Phase 3
15 Anti-Infective Agents, Local Phase 2, Phase 3
16 Pharmaceutical Solutions Phase 3
17
Zinc Approved, Investigational Phase 1, Phase 2 7440-66-6 32051
18
Nitric Oxide Approved Phase 1, Phase 2 10102-43-9 145068
19
Acetylcholine Approved, Investigational Phase 2 51-84-3 187
20
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
21
Vitamin C Approved, Nutraceutical Phase 1, Phase 2 50-81-7 5785 54670067
22
Maleic acid Experimental Phase 1, Phase 2 110-16-7 444266
23 Micronutrients Phase 1, Phase 2
24 Trace Elements Phase 1, Phase 2
25 Chelating Agents Phase 1, Phase 2
26 Zinc Supplement Phase 1, Phase 2
27 Protective Agents Phase 1, Phase 2
28 Respiratory System Agents Phase 1, Phase 2
29 Anti-Asthmatic Agents Phase 1, Phase 2
30 Antioxidants Phase 1, Phase 2
31 Bronchodilator Agents Phase 1, Phase 2
32 Endothelium-Dependent Relaxing Factors Phase 1, Phase 2
33 Radiation-Protective Agents Phase 2
34 Immunologic Factors Phase 2
35 Ammonium trichloro(dioxoethylene-O,O'-)tellurate Phase 2
36 Adjuvants, Immunologic Phase 2
37 Antiviral Agents Phase 2
38 abobotulinumtoxinA Phase 2
39 Botulinum Toxins, Type A Phase 2
40 Botulinum Toxins Phase 2
41 Cholinergic Agents Phase 2
42 HIV Protease Inhibitors Phase 2
43
protease inhibitors Phase 2
44 Proteasome Inhibitors Phase 2
45 Ophthalmic Solutions Phase 2
46 Androgens Phase 2
47 Mitogens Phase 1, Phase 2
48 Anticonvulsants Phase 2
49 Psychotropic Drugs Phase 2
50
Bimatoprost Approved, Investigational Phase 1 155206-00-1 5311027

Interventional clinical trials:

(show top 50) (show all 121)
# Name Status NCT ID Phase Drugs
1 Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial Unknown status NCT02999737 Phase 4
2 Minoxidil in Treatment of Androgenetic Alopecia Completed NCT04090801 Phase 4 Topical minoxidil 5% in 90% ethanol and 5% propylene glycol;Topical minoxidil 5% in pure ethanol alone
3 the Effect of Adipose Derived Stem Cells Combined With Platelet Rich Plasma Versus Platelet Rich Plasma Alone on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial Recruiting NCT03388840 Phase 4
4 Efficacy and Tolerability of N-Acetyl- Cysteine for Treatment of The Early-onset Androgenetic Alopecia in Men Recruiting NCT04209803 Phase 4 Minoxidil 5% topically and oral NAC 600 mg
5 Topical Cetirizine Gel Versus Minoxidil 5% Gel in Treatment of Androgenetic Alopecia Not yet recruiting NCT04293822 Phase 4 Cetirizine;Minoxidil
6 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
7 BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA Unknown status NCT01655108 Phase 3 Minoxidil;Saline
8 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% & 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia Completed NCT03742518 Phase 2, Phase 3 Topical SM04554 solution;Topical SM04554 solution;Topical vehicle solution
9 Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
10 A Multicentre, Randomized, Double-blind, Parallel-group, Controlled Study, to Assess the Efficacy and Safety of P-3074 Cutaneous Spray, Solution, in the Treatment of Male Pattern Baldness Completed NCT03004469 Phase 3 P-3074;Finasteride;P-3074 Vehicle;Finasteride Placebo
11 A Prospective, Randomized, Controlled, Double-Blind Study That Evaluates the Safety and Efficacy of Three Active REVIAN Caps Versus a Non-Active REVIAN Cap (Sham) in Participants With Pattern Hair Loss (Androgenic Alopecia) Completed NCT04019795 Phase 3
12 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia) Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
13 A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
14 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - Androgenetic Alopecia (MINALO3004, NCT01145625) Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
15 A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
16 A Double-Blind, Randomized, Placebo-Controlled Trial of the Efficacy and Safety of 5 Percent Minoxidil Foam in the Treatment of Androgenetic Alopecia in Males Completed NCT00151515 Phase 3 minoxidil
17 Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
18 A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
19 An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V) Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
20 Evaluating the Efficacy of Topical Herbal Solution on the Treatment of Androgenetic Alopecia and Comparison With Minoxidil 5%: A Double-Blind, Randomized, Clinical Trial Study Completed NCT03753113 Phase 3 Topical Herbal Solution;Topical Minoxidil 5%
21 Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Moderate Androgenetic Alopecia Concerning Hair Volume Completed NCT00958750 Phase 3 minoxidil
22 The Role of Cetirizine in Androgenetic Alopecia in Females Recruiting NCT04481412 Phase 2, Phase 3 Topical cetirizine;Placebo;Topical minoxidil
23 National, Multicentre, Randomized, Double-blind, Double-dummy Phase III Clinical Trial to Evaluate the Efficacy and Safety of Finlândia Hair Lotion Association in the Treatment of Androgenetic Alopecia. Not yet recruiting NCT04594018 Phase 3 Finlândia Association + finasteride placebo;Minoxidil + finasteride
24 A Randomized, Double Blind, Parallel-group Study to Evaluate the Efficacy and Safety of a New Pharmaceutical Form Minoxidil 5% for the Treatment of Androgenetic Alopecia in Men for 24 Weeks Not yet recruiting NCT04721548 Phase 3 Minoxidil Topical Foam;Placebo
25 A Phase 2 Multicenter, Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men Unknown status NCT00471510 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
26 A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For Treatment Of Androgenetic Alopecia (AGA) Unknown status NCT01643629 Phase 1, Phase 2
27 A Pilot Study of the Efficacy in Treatment of Female Pattern Hair Loss Using 5% Minoxidil Solution Combinded With Oral Chelated Zinc Supplement Unknown status NCT01662089 Phase 1, Phase 2 15 mg Chelate zinc supplement;Placebo drug supplement
28 Safety and Efficacy of Nitric Oxide Gel in Promoting Hair Growth in Male Human Subjects With Androgenetic Alopecia Unknown status NCT01347957 Phase 1, Phase 2
29 Phase 2 Study of Topical AS101 for the Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women Unknown status NCT00418249 Phase 2 AS101
30 A Multi-center, Randomized, Controlled, Double-blind Study That Evaluates a Low Level Laser Therapy Over-the-counter at Home Device, Theradomeâ„¢ LH80 PRO vs a Sham Device, for Promoting Hair Growth in Males Diagnosed With Androgenetic Alopecia Unknown status NCT02528552 Phase 2
31 The Clinical Effects of HSC (Hair Stimulating Complex) on Hair Growth in Androgenetic Alopecia: A Phase I/II Clinical Trial Unknown status NCT01501617 Phase 1, Phase 2
32 A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate Safety & Efficacy Of Autologous Human Platelet Lysate For Treatment Of Androgenetic Alopecia In Patients Undergoing Hair Transplant Unknown status NCT01644422 Phase 1, Phase 2
33 A Prospective, Single Center, Open Label, Proof of Principle Study to Assess the Efficacy and Safety of 150 Units of Botulinum Toxin-A Intra-Muscular Injection in the Prevention of Hair Loss in Men With Androgenetic Alopecia Completed NCT00965640 Phase 2 Botulinum Toxin - A injections
34 A Phase 2 Multicenter, Randomized, Placebo- and Comparator-Controlled, Double-Blind Parallel Group Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men Completed NCT00418730 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
35 A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing Completed NCT02503137 Phase 2 Topical SM04554 solution;Topical Vehicle solution
36 Topical Bimatoprost Effect on Androgen Dependent Hair Follicles Completed NCT02170662 Phase 2 Bimatoprost;Placebo
37 A Randomized, Double-Blind, Active-controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of ENERGI-F701 Solution in Female Subjects With Hair Loss Completed NCT03351322 Phase 2 ENERGI-F701;Regaine
38 A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) Completed NCT02275351 Phase 2 SM04554;Vehicle
39 A Phase 2, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Solution 5%, Minoxidil Solution 5%, and Vehicle Solution, Applied Twice-daily for 26 Weeks in Males With Androgenetic Alopecia (AGA) Completed NCT02279823 Phase 2 CB-03-01 solution;Minoxidil Solution 5%;Placebo solution
40 Evaluation of the Efficacy of Hcap Formula Nutrition Supplement for Treatment of Men With Androgenic Alopecia: A Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT02150187 Phase 2
41 A Randomised, Double-blind, Placebo-controlled Phase 2 Trial of FOL-005 to Investigate Efficacy on Hair Growth on Scalp Skin in Healthy Volunteers Completed NCT03467412 Phase 2 FOL-005;Placebo
42 A Randomized Controlled Trial Comparing Platelet Rich Plasma (PRP) to Minoxidil Foam for Treatment of Androgenic Alopecia in Women Completed NCT03488108 Phase 1, Phase 2 Minoxidil Foam
43 Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia Completed NCT01325337 Phase 2 bimatoprost Formulation A;bimatoprost Formulation B;bimatoprost Formulation C;bimatoprost vehicle solution;minoxidil 5% solution
44 A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) Completed NCT01904721 Phase 2 Bimatoprost Solution 1;Bimatoprost Solution 2;Bimatoprost Vehicle
45 Investigator-Initiated, Double Blind, Two-Armed, Placebo-Controlled, Randomized Clinical Trial With an Open-Label Extension Phase, to Investigate Efficacy of 5% Minoxidil Topical Foam Twice Daily in Men With Androgenetic Alopecia in the Temple and Vertex Region Concerning Hair Volume Over 24 / 104 Weeks Completed NCT01319370 Phase 2 Minoxidil;vehicle of 5% Minoxidil topical foam
46 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males Completed NCT02781311 Phase 2 Setipiprant;Placebo;Finasteride
47 Adipose Tissue Derived Stem Cell Based Hair Restoration Therapy for Androgenetic Alopecia Completed NCT02865421 Phase 2 stem cells;platelet rich plasma
48 Randomized, Single-centre, Double-blind, Placebo-controlled, Phase I / IIa Study to Evaluate the Safety and Efficacy of Human Autologous Hair Follicle Dermal Sheath Cup Cells (DSCC) in Women and Men With Androgenetic Alopecia. Completed NCT01286649 Phase 1, Phase 2
49 An Open-Label Safety, Tolerability, and Efficacy Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution Completed NCT03495817 Phase 2 ATI-50002
50 A Single-center, Active-controlled, Randomized, Double-blind, Proof of Concept Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application in Male Patients With Androgenetic Alopecia Completed NCT02280603 Phase 1, Phase 2 DA-4001C;5% minoxidil

Search NIH Clinical Center for Alopecia, Androgenetic, 1

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Alopecia, Androgenetic, 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Alopecia, Androgenetic, 1:
RepliCel Hair-01 (RCH-01), hair follicle-derived mesenchymal stem cells for treatment of androgenetic alopecia
Embryonic/Adult Cultured Cells Related to Alopecia, Androgenetic, 1:
Hair follicle mesenchymal stem cells (RepliCel Hair-01)
Sources

Genetic Tests for Alopecia, Androgenetic, 1

About this section
Sources

Anatomical Context for Alopecia, Androgenetic, 1

About this section

MalaCards organs/tissues related to Alopecia, Androgenetic, 1:

40
Prostate, Skin, Ovary, Breast, Heart, Endothelial, Brain
Sources

Publications for Alopecia, Androgenetic, 1

About this section

Articles related to Alopecia, Androgenetic, 1:

(show top 50) (show all 1585)
# Title Authors PMID Year
1
Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. 57 61
18304493 2008
2
The hairless gene in androgenetic alopecia: results of a systematic mutation screening and a family-based association approach. 57 61
11966690 2002
3
Androgenetic alopecia in heterozygous carriers of a mutation in the human hairless gene. 57 61
10827399 2000
4
The inheritance of common baldness: two B or not two B? 61 57
6512048 1984
5
Genetic analysis of male pattern baldness and the 5alpha-reductase genes. 57
9620288 1998
6
Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. 57
7849715 1994
7
Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. 57
8334753 1993
8
Patterned loss of hair in man; types and incidence. 57
14819896 1951
9
Novel anti-prostate cancer curcumin analogues that enhance androgen receptor degradation activity. 61 54
19663790 2009
10
Recent positive selection of a human androgen receptor/ectodysplasin A2 receptor haplotype and its relationship to male pattern baldness. 54 61
19373488 2009
11
Evaluation of androgen receptor gene as a candidate gene in female androgenetic alopecia. 54 61
19538365 2009
12
Androgen receptor copy number variation and androgenetic alopecia: a case-control study. 54 61
19340294 2009
13
Finasteride treatment and neuroactive steroid formation. 54 61
19655698 2009
14
Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old. 61 54
18363752 2008
15
Men with Kennedy disease have a reduced risk of androgenetic alopecia. 54 61
17596176 2007
16
Baldness and the androgen receptor: the AR polyglycine repeat polymorphism does not confer susceptibility to androgenetic alopecia. 54 61
17256155 2007
17
[Premature androgenetic alopecia in adult male with nonclassic 21-OH deficiency. A novel nonsense CYP21A2 mutation (Y336X) in 2 affected siblings]. 54 61
17145028 2006
18
A new look at the 5alpha-reductase inhibitor finasteride. 54 61
16834758 2006
19
The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia. 61 54
15824176 2005
20
Solubilization and solid-state characterization of a poorly soluble 5-alpha reductase inhibitor. 54 61
15285330 2004
21
Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. 54 61
14729013 2004
22
Testosterone metabolism in human skin cells in vitro and its interaction with estradiol and dutasteride. 54 61
14528059 2003
23
Analysis of genetic polymorphisms of steroid 5alpha-reductase type 1 and 2 genes in Korean men with androgenetic alopecia. 54 61
12670724 2003
24
Male-pattern baldness is common in men with X-linked recessive ichthyosis. 54 61
14571075 2003
25
Acne: effect of hormones on pathogenesis and management. 54 61
12358558 2002
26
Steroid sulfatase in the human hair follicle concentrates in the dermal papilla. 61 54
11886493 2001
27
Androgen responsive genes as they affect hair growth. 54 61
11399535 2001
28
The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles. 54 61
11125319 2000
29
[Hormonal profile in men with premature androgenic alopecia]. 54 61
10953626 2000
30
[Treatment of androgenetic alopecia in the man using systemic 5 alpha-reductase inhibition]. 61 54
9879479 1998
31
Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. 61 54
9284093 1997
32
Hormonal status in postmenopausal androgenetic alopecia. 61 54
1478763 1992
33
Oral minoxidil treatment for hair loss: A review of efficacy and safety. 61
32622136 2021
34
Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. 61
31403367 2021
35
Reply to Kim et al letter on "The effect of platelet-rich plasma on female androgenetic alopecia: A randomized controlled trial". 61
33549651 2021
36
[A new treatment for androgenetic alopecia : platelet-rich plasma injections]. 61
33543858 2021
37
Association of Fibrosis in Bulge Portion with Hair Follicle Miniaturization in Androgenetic Alopecia. 61
33539849 2021
38
Favorable effects of microneedling on long-standing androgenetic alopecia in an elderly man: A case report. 61
32500595 2021
39
Transcriptome profiling of pilosebaceous units in male androgenetic alopecia reveals altered junctional networks. 61
33607114 2021
40
The role of prostaglandins in androgenetic alopecia. 61
33528035 2021
41
Reply to: << The effect of platelet-rich plasma on female androgenetic alopecia: A randomized controlled trial >>. 61
33549654 2021
42
Low-Level Laser Therapy for Androgenetic Alopecia. 61
33130013 2021
43
Incidence and Factors Associated With Androgenetic Alopecia Among Transgender and Gender-Diverse Patients Treated With Masculinizing Hormone Therapy. 61
33566078 2021
44
Radiofrequency Microneedling: A Comprehensive and Critical Review. 61
33577211 2021
45
Paper 2. Epigallocatechin Gallate and Tannic Acid Based Formulations of Finasteride for Dermal Administration and Chemoembolization. 61
33035538 2021
46
Artificial hair implantation for hair restoration. 61
33565339 2021
47
Platelet lysate: a promising candidate in regenerative medicine. 61
33543999 2021
48
Use of vibrating anesthetic device reduces the pain of mesotherapy injections: A randomized split-scalp study. 61
32640097 2021
49
miRNA microarray profiling in patients with androgenic alopecia and the effects of miR-133b on hair growth. 61
33290799 2021
50
Alopecia and the Microbiome: A Future Therapeutic Target? 61
33476584 2021
Sources

Variations for Alopecia, Androgenetic, 1

About this section
Sources

Expression for Alopecia, Androgenetic, 1

About this section
Search GEO for disease gene expression data for Alopecia, Androgenetic, 1.
Sources

Pathways for Alopecia, Androgenetic, 1

About this section

Pathways related to Alopecia, Androgenetic, 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Translation Non-genomic (rapid) action of Androgen Receptor 23
Show member pathways
 11.9 SRD5A2 SRD5A1 AR
2
Metabolism of steroid hormones 65
Show member pathways
 11.16 SRD5A2 SRD5A1 CYP21A2 CYP19A1
3
Estrogen metabolism 1
Show member pathways
 10.9 STS CYP19A1
4
Steroid hormone biosynthesis 36
Show member pathways
 10.85 STS SRD5A2 SRD5A1 CYP21A2 CYP19A1
5
superpathway of steroid hormone biosynthesis 1
Show member pathways
 10.65 SRD5A2 SRD5A1 CYP21A2
6
Nongenotropic Androgen signaling 1
10.58 SHBG AR
7
Aromatase Inhibitor Pathway (Multiple Tissues), Pharmacodynamics 60
9.96 STS CYP19A1
Sources

GO Terms for Alopecia, Androgenetic, 1

About this section

Cellular components related to Alopecia, Androgenetic, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum membrane GO:0005789 9.55 STS SRD5A2 SRD5A1 CYP21A2 CYP19A1
2 intracellular membrane-bounded organelle GO:0043231 9.35 STS SRD5A2 SRD5A1 CYP21A2 CYP19A1
3 organelle membrane GO:0031090 8.92 SRD5A2 SRD5A1 CYP21A2 CYP19A1

Biological processes related to Alopecia, Androgenetic, 1 according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of extrinsic apoptotic signaling pathway GO:2001237 9.55 CFLAR AR
2 cellular response to estradiol stimulus GO:0071392 9.54 SRD5A1 CFLAR
3 response to testosterone GO:0033574 9.52 SRD5A1 CFLAR
4 cellular response to dexamethasone stimulus GO:0071549 9.51 SRD5A1 CFLAR
5 sterol metabolic process GO:0016125 9.49 CYP21A2 CYP19A1
6 sex differentiation GO:0007548 9.48 SRD5A2 SRD5A1
7 male genitalia development GO:0030539 9.46 SRD5A2 SRD5A1
8 steroid metabolic process GO:0008202 9.46 STS SRD5A2 SRD5A1 CYP21A2
9 androgen metabolic process GO:0008209 9.43 SRD5A2 SRD5A1
10 androgen biosynthetic process GO:0006702 9.4 SRD5A2 SRD5A1
11 cellular response to testosterone stimulus GO:0071394 9.37 SRD5A1 AR
12 androgen catabolic process GO:0006710 9.32 SRD5A1 CYP19A1
13 positive regulation of integrin biosynthetic process GO:0045726 9.26 TGFB2 AR
14 male gonad development GO:0008584 9.26 TGFB2 SRD5A2 SRD5A1 AR
15 steroid biosynthetic process GO:0006694 8.92 SRD5A2 SRD5A1 CYP21A2 CYP19A1

Molecular functions related to Alopecia, Androgenetic, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.71 SRD5A2 SRD5A1 CYP21A2 CYP19A1
2 steroid hydroxylase activity GO:0008395 9.37 CYP21A2 CYP19A1
3 oxidoreductase activity, acting on the CH-CH group of donors GO:0016627 9.32 SRD5A2 SRD5A1
4 androgen binding GO:0005497 9.26 SHBG AR
5 3-oxo-5-alpha-steroid 4-dehydrogenase activity GO:0003865 9.16 SRD5A2 SRD5A1
6 cholestenone 5-alpha-reductase activity GO:0047751 8.96 SRD5A2 SRD5A1
7 steroid binding GO:0005496 8.8 SHBG CYP21A2 AR
Sources

Sources for Alopecia, Androgenetic, 1

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....